Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage.

Despite the availability of 24 marketed molecules, the development of new targeted molecules is ongoing with a total of 243 molecules in RA. With seven molecules currently reaching phase III, we can expect an increase in the armamentarium in the years to come.